Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694691 · ClinicalTrials.gov registry record · NA
Developing Viability Index for Machine Perfused Livers
A NA study of Liver Cirrhoses, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03694691: Recruiting NA study of Liver Cirrhoses, sponsored by Massachusetts General Hospital.
NCT03694691 is a NA study of Liver Cirrhoses that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694691, a NA study of Liver Cirrhoses, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collecting biopsies from transplanted livers before and after implantation to correlate metabolite and gene expression with post-transplant function. This data will help develop a viability index for machine perfused livers.
Primary Outcome
The primary endpoint is peak transaminase values since transaminase elevation is a marker of hepatocyte injury
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Liver Biopsy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2030-06-01 |
| Phase | NA |
What NCT03694691 shows while recruiting
NCT03694691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Liver Cirrhoses appearing as the primary indexed condition, and to 1 intervention - of which Liver Biopsy is the first listed.
NCT03694691 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03694691 about?
NCT03694691 is a clinical study titled "Developing Viability Index for Machine Perfused Livers". Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collectin...
What is the current status of trial NCT03694691?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-10-01. Estimated completion is 2030-06-01.
What conditions does trial NCT03694691 study?
This clinical trial studies the following conditions: Liver Cirrhoses.
What interventions are being tested in trial NCT03694691?
The interventions under investigation include: Liver Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03694691?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03694691 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cirrhoses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03694691's enrollment target sits among peer trials
60 1165th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI